Home » Stocks » NWBO

Northwest Biotherapeutics, Inc. (NWBO)

Stock Price: $1.26 USD -0.07 (-5.26%)
Updated Jul 23, 2021 3:59 PM EDT - Market closed
Market Cap 1.10B
Revenue (ttm) 960,000
Net Income (ttm) -536.47M
Shares Out 834.61M
EPS (ttm) -0.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $1.26
Previous Close $1.33
Change ($) -0.07
Change (%) -5.26%
Day's Open 1.34
Day's Range 1.25 - 1.35
Day's Volume 2,529,190
52-Week Range 0.29 - 2.51


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Generally speaking, biotech is a pretty innovative industry -- with a few notable bad apples.

Other stocks mentioned: CVM, CYDY
2 weeks ago - The Motley Fool

Are these the best biotech penny stocks to watch right now? The post Best Biotech Penny Stocks In Summer 2021?

Other stocks mentioned: ACST, ADMP, AMPE, BIOL, ENZC, JAGX
3 weeks ago - PennyStocks

Looking for 7 penny stocks that could be buy the dip candidates? Check these out The post 7 Penny Stocks to Watch With Crypto News Sparking a Market Dip appeared first on Penny Stocks to Buy, Picks, New...

Other stocks mentioned: ARPO, ATOS, GSAT, IDEX, PLIN, SENS
2 months ago - PennyStocks

BETHESDA, Md., May 12, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today ann...

2 months ago - PRNewsWire

BETHESDA, Md., March 16, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today a...

4 months ago - PRNewsWire

NWBO has run an 18-year long trial in GBM, one of the deadliest of cancers. It has been mired in controversies, and it has no cash.

7 months ago - Seeking Alpha

In a short period of time, this immunotherapy biotech could either become a multi-bagger or trade near $0.

Other stocks mentioned: NVCR
8 months ago - The Motley Fool

With Data Lock just announced, Top Line Date is imminent.

9 months ago - Seeking Alpha

About NWBO

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L that is in Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The compa... [Read more...]

Linda Powers
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2020, NWBO's revenue was $1.29 million, a decrease of -46.43% compared to the previous year's $2.41 million. Losses were -$529.82 million, 2,445.7% more than in 2019.

Financial Statements